Welcome to our dedicated page for MapLight Therapeutics news (Ticker: MPLT), a resource for investors and traders seeking the latest updates and insights on MapLight Therapeutics stock.
MapLight Therapeutics, Inc. (Nasdaq: MPLT) is a clinical-stage biopharmaceutical company focused on debilitating central nervous system disorders, and its news flow reflects the progress of a multi-program CNS pipeline. Company announcements describe clinical trial milestones, regulatory designations, financial updates, and research collaborations tied to its circuit-focused drug discovery approach.
Recent news highlights include updates on Phase 2 studies such as ZEPHYR for schizophrenia and IRIS for autism spectrum disorder, along with the VISTA trial for hallucinations and delusions associated with Alzheimer’s disease psychosis. MapLight has reported accelerated enrollment in certain trials and provided guidance on expected timing for topline results, which are key events for investors and observers tracking the development of its product candidates.
The company has also disclosed that the U.S. Food and Drug Administration granted Fast Track designation to ML-007C-MA for Alzheimer’s disease psychosis, and that a Phase 1 study showed a generally favorable safety and tolerability profile in healthy elderly participants. In addition, MapLight has announced a strategic collaboration with SandboxAQ to apply AI-driven molecular simulation to novel G protein-coupled receptor targets for CNS disorders.
News items further cover MapLight’s initial public offering on the Nasdaq Global Select Market under the symbol MPLT, a concurrent private placement, and subsequent financial updates. Visitors to this page can review these press releases and other company communications to follow clinical progress, regulatory interactions, capital markets activity, and partnership developments related to MapLight’s CNS-focused pipeline.
MapLight Therapeutics (NASDAQ: MPLT) priced its initial public offering of 14,750,000 shares at $17.00 per share and granted underwriters a 30-day option to buy up to 2,212,500 additional shares.
The company also announced a concurrent private placement of 476,707 shares to affiliates of Goldman Sachs at the IPO price. Gross proceeds from the IPO and private placement are expected to be approximately $258.9 million before underwriting discounts, commissions, and expenses. Shares are expected to begin trading on the Nasdaq Global Market on October 27, 2025 under symbol MPLT, with the offering expected to close on October 28, 2025 subject to customary closing conditions.